Accueil   Diary - News   All news Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

Alizé Pharma 3 : data from its AZP-3404 program in syndromes of severe insulin resistance

 

AZP-3404, an optimized peptide derived from IGFBP-2, improves glucose control in a preclinical model of severe insulin resistance through a new and unique mechanism of action

 

Lyon, France, March 21, 2019 - Alizé Pharma 3, a transatlantic company specialized in developing therapeutic peptides for the treatment of rare endocrine and metabolic diseases, today announces it will present preclinical results from its AZP-3404 program in syndromes of severe insulin resistance during the Annual Meeting of the Endocrine Society in New Orleans on March 23-26, 2019.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree